Biosyent's total assets for Q4 2024 were C$41.36M, a decrease of -9.04% from the previous quarter. TSE:RX total liabilities were C$6.36M for the fiscal quarter, a -21.76% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.